The therapeutic potential of orphan GPCRs, GPR35 and GPR55

Frontiers in Pharmacology

Volumn 6, Issue MAR, 2015, Pages

  Reggio, Patricia Hodapp ^a   Shore, Derek M ^a  

^a UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 3 (2 HYDROXYBENZYL) 5 ISOPROPYL 8 METHYL 2H CHROMEN 2 ONE; BETA ARRESTIN; CALCIUM CHANNEL N TYPE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR8; CID 16020046; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 35; G PROTEIN COUPLED RECEPTOR 55; INTERLEUKIN 4; KYNURENIC ACID; KYNURENINE; ORPHAN NUCLEAR RECEPTOR; PROTEIN INHIBITOR; PURINERGIC RECEPTOR; TETRAHYDROMAGNOLOL; UNCLASSIFIED DRUG; ZAPRINAST;

ACUTE HEART INFARCTION; AMINO TERMINAL SEQUENCE; ARTICLE; BILE DUCT CARCINOMA; BINDING AFFINITY; BREAST CANCER; CARBOXY TERMINAL SEQUENCE; CAUDATE NUCLEUS; COPY NUMBER VARIATION; CORPUS STRIATUM; CYTOKINE RELEASE; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; HUMAN; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INTERNALIZATION; LIPID BILAYER; MENTAL DEFICIENCY; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; MONOCYTE; NATURAL KILLER T CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSTEOBLAST; OSTEOCLAST; OVARY CANCER; PANCREAS CANCER; PRIMARY SCLEROSING CHOLANGITIS; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PUTAMEN; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN CANCER; STATIC ELECTRICITY; SYNAPSE; SYNAPTIC TRANSMISSION; THYMUS; ULCERATIVE COLITIS; UPREGULATION;

EID: 84926645822     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00069     Document Type: Article

References (121)

1. Abed, E., Labelle, D., Martineau, C., Loghin, A., and Moreau, R. (2009). Expression of transient receptor potential (TRP) channels in human and murine osteoblast-like cells. Mol Membr Biol 26, 146-158. doi: 10.1080/09687680802612721.
2. Alkondon, M., Pereira, E.F., Todd, S.W., Randall, W.R., Lane, M., and Albuquerque, E.X. (2014). Functional G-protein coupled receptor 35 is expressed by neurons in the CA1 field of the hippocampus. Biochem Pharmacol. doi: 10.1016/j.bcp.2014.12.009.
3. Andradas, C., Caffarel, M.M., Perez-Gomez, E., Salazar, M., Lorente, M., Velasco, G., Guzman, M., and Sanchez, C. (2010). The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 30, 245-252.
4. Andradas, C., Caffarel, M.M., Perez-Gomez, E., Salazar, M., Lorente, M., Velasco, G., Guzman, M., and Sanchez, C. (2011). The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 30, 245-252. doi: 10.1038/onc.2010.402.
5. Arad, Y., Spadaro, L.A., Goodman, K., Newstein, D., and Guerci, A.D. (2000). Prediction of coronary events with electron beam computed tomography. J Am Coll Cardiol 36, 1253-1260.
6. Barth, M.C., Ahluwalia, N., Anderson, T.J., Hardy, G.J., Sinha, S., Alvarez-Cardona, J.A., Pruitt, I.E., Rhee, E.P., Colvin, R.A., and Gerszten, R.E. (2009). Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions. J Biol Chem 284, 19189-19195.
7. Berlinguer-Palmini, R., Masi, A., Narducci, R., Cavone, L., Maratea, D., Cozzi, A., Sili, M., Moroni, F., and Mannaioni, G. (2013). GPR35 activation reduces Ca2+ transients and contributes to the kynurenic acid-dependent reduction of synaptic activity at CA3-CA1 synapses. PLoS One 8, e82180. doi: 10.1371/journal.pone.0082180.
8. Brown, A.J., Daniels, D.A., Kassim, M., Brown, S., Haslam, C.P., Terrell, V.R., Brown, J., Nichols, P.L., Staton, P.C., Wise, A., and Dowell, S.J. (2011). Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J Pharmacol Exp Ther 337, 236-246.
9. Brown, A.J., and Wise, A. (2001). Identification of modulators of GPR55 activity.
10. Cherezov, V., Rosenbaum, D.M., Hanson, M.A., Rasmussen, S.G., Thian, F.S., Kobilka, T.S., Choi, H.J., Kuhn, P., Weis, W.I., Kobilka, B.K., and Stevens, R.C. (2007). High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318, 1258-1265.
11. Conklin, B.R., Farfel, Z., Lustig, K.D., Julius, D., and Bourne, H.R. (1993). Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha. Nature 363, 274-276. doi: 10.1038/363274a0.
12. Cosi, C., Mannaioni, G., Cozzi, A., Carla, V., Sili, M., Cavone, L., Maratea, D., and Moroni, F. (2011). G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: Studies on the antinociceptive effects of kynurenic acid and zaprinast. Neuropharmacology 60, 1227-1231. doi: 10.1016/j.neuropharm.2010.11.014.
13. Coward, P., Chan, S.D., Wada, H.G., Humphries, G.M., and Conklin, B.R. (1999). Chimeric G proteins allow a high-throughput signaling assay of Gi-coupled receptors. Anal Biochem 270, 242-248. doi: 10.1006/abio.1999.4061.
14. Demorrow, S., Glaser, S., Francis, H., Venter, J., Vaculin, B., Vaculin, S., and Alpini, G. (2007). Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of Fas and Fas ligand to lipid rafts. J Biol Chem 282, 13098-13113. doi: 10.1074/jbc.M608238200.
15. Deng, H., and Fang, Y. (2012). Anti-inflammatory gallic Acid and wedelolactone are G protein-coupled receptor-35 agonists. Pharmacology 89, 211-219. doi: 10.1159/000337184.
16. Deng, H., Hu, H., and Fang, Y. (2011). Tyrphostin analogs are GPR35 agonists. FEBS Lett 585, 1957-1962. doi: 10.1016/j.febslet.2011.05.026.
17. Deng, H., Hu, H., and Fang, Y. (2012). Multiple tyrosine metabolites are GPR35 agonists. Sci Rep 2, 373. doi: 10.1038/srep00373.
18. Diaz-Arteaga, A., Vazquez, M.J., Vazquez-Martinez, R., Pulido, M.R., Suarez, J., Velasquez, D.A., Lopez, M., Ross, R.A., De Fonseca, F.R., Bermudez-Silva, F.J., Malagon, M.M., Dieguez, C., and Nogueiras, R. (2012). The atypical cannabinoid O-1602 stimulates food intake and adiposity in rats. Diabetes Obes Metab 14, 234-243. doi: 10.1111/j.1463-1326.2011.01515.x.
19. Drmota, T., Greasley, P., and Groblewski, T. (2004). Screening assays for cannabinoidligand type modulators of GPR55. USA patent application.
20. Drzazga, A., Sowinska, A., and Koziolkiewicz, M. (2014). Lysophosphatidylcholine and lysophosphatidylinositol-Novel Promising Signaling Molecules and Their Possible Therapeutic Activity. Acta Poloniae Pharmaceutica-Drug Research 71, 887-899.
21. Elayat, A.A., El-Naggar, M.M., and Tahir, M. (1995). An immunocytochemical and morphometric study of the rat pancreatic islets. J Anat 186 (Pt 3), 629-637.
22. Ellinghaus, D., Folseraas, T., Holm, K., Ellinghaus, E., Melum, E., Balschun, T., Laerdahl, J.K., Shiryaev, A., Gotthardt, D.N., Weismuller, T.J., Schramm, C., Wittig, M., Bergquist, A., Bjornsson, E., Marschall, H.U., Vatn, M., Teufel, A., Rust, C., Gieger, C., Wichmann, H.E., Runz, H., Sterneck, M., Rupp, C., Braun, F., Weersma, R.K., Wijmenga, C., Ponsioen, C.Y., Mathew, C.G., Rutgeerts, P., Vermeire, S., Schrumpf, E., Hov, J.R., Manns, M.P., Boberg, K.M., Schreiber, S., Franke, A., and Karlsen, T.H. (2013). Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology 58, 1074-1083. doi: 10.1002/hep.25977.
23. Falasca, M., and Corda, D. (1994). Elevated levels and mitogenic activity of lysophosphatidylinositol in k-ras-transformed epithelial cells. Eur J Biochem 221, 383-389.
24. Falasca, M., Iurisci, C., Carvelli, A., Sacchetti, A., and Corda, D. (1998). Release of the mitogen lysophosphatidylinositol from H-Ras-transformed fibroblasts; a possible mechanism of autocrine control of cell proliferation. Oncogene 16, 2357-2365. doi: 10.1038/sj.onc.1201758.
25. Fallarini, S., Magliulo, L., Paoletti, T., De Lalla, C., and Lombardi, G. (2010). Expression of functional GPR35 in human iNKT cells. Biochem Biophys Res Commun 398, 420-425. doi: 10.1016/j.bbrc.2010.06.091.
26. Ford, L.A., Roelofs, A.J., Anavi-Goffer, S., Mowat, L., Simpson, D.G., Irving, A.J., Rogers, M.J., Rajnicek, A.M., and Ross, R.A. (2010). A role for L-alphalysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol 160, 762-771.
27. Franck, M.C., Stenqvist, A., Li, L., Hao, J., Usoskin, D., Xu, X., Wiesenfeld-Hallin, Z., and Ernfors, P. (2011). Essential role of Ret for defining non-peptidergic nociceptor phenotypes and functions in the adult mouse. Eur J Neurosci 33, 1385-1400. doi: 10.1111/j.1460-9568.2011.07634.x.
28. Guo, J., Williams, D.J., Puhl, H.L., 3rd, and Ikeda, S.R. (2008). Inhibition of N-type calcium channels by activation of GPR35, an orphan receptor, heterologously expressed in rat sympathetic neurons. J Pharmacol Exp Ther 324, 342-351. doi: 10.1124/jpet.107.127266.
29. Henstridge, C.M. (2012). Off-target cannabinoid effects mediated by GPR55. Pharmacology 89, 179-187. doi: 10.1159/000336872.
30. Henstridge, C.M., Balenga, N.A., Ford, L.A., Ross, R.A., Waldhoer, M., and Irving, A.J. (2009). The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoAdependent Ca2+ signaling and NFAT activation. Faseb J 23, 183-193.
31. Henstridge, C.M., Balenga, N.A., Schroder, R., Kargl, J.K., Platzer, W., Martini, L., Arthur, S., Penman, J., Whistler, J.L., Kostenis, E., Waldhoer, M., and Irving, A.J. (2010). GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol 160, 604-614.
32. Heynen-Genel, S., Dahl, R., Shi, S., Milan, L., Hariharan, S., Bravo, Y., Sergienko, E., Hedrick, M., Dad, S., Stonich, D., Su, Y., Vicchiarelli, M., Mangravita-Novo, A., Smith, L.H., Chung, T.D.Y., Sharir, H., Barak, L.S., and Abood, M.E. (2010). "Screening for Selective Ligands for GPR55 - Agonists", in: Probe Reports NIH Molecular Libraries Program.).
33. Hilger, A., Schramm, C., Pennimpede, T., Wittler, L., Dworschak, G.C., Bartels, E., Engels, H., Zink, A.M., Degenhardt, F., Muller, A.M., Schmiedeke, E., Grasshoff-Derr, S., Marzheuser, S., Hosie, S., Holland-Cunz, S., Wijers, C.H., Marcelis, C.L., Van Rooij, I.A., Hildebrandt, F., Herrmann, B.G., Nothen, M.M., Ludwig, M., Reutter, H., and Draaken, M. (2013). De novo microduplications at 1q41, 2q37.3, and 8q24.3 in patients with VATER/VACTERL association. Eur J Hum Genet 21, 1377-1382. doi: 10.1038/ejhg.2013.58.
34. Horikawa, Y., Oda, N., Cox, N.J., Li, X., Orho-Melander, M., Hara, M., Hinokio, Y., Lindner, T.H., Mashima, H., Schwarz, P.E., Del Bosque-Plata, L., Horikawa, Y., Oda, Y., Yoshiuchi, I., Colilla, S., Polonsky, K.S., Wei, S., Concannon, P., Iwasaki, N., Schulze, J., Baier, L.J., Bogardus, C., Groop, L., Boerwinkle, E., Hanis, C.L., and Bell, G.I. (2000). Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 26, 163-175. doi: 10.1038/79876.
35. Huang, L., Ramirez, J.C., Frampton, G.A., Golden, L.E., Quinn, M.A., Pae, H.Y., Horvat, D., Liang, L.J., and Demorrow, S. (2011). Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor. Lab Invest 91, 1007-1017. doi: 10.1038/labinvest.2011.62.
36. Hurst, D.P., Lynch, D.L., Barnett-Norris, J., Hyatt, S.M., Seltzman, H.H., Zhong, M., Song, Z.H., Nie, J., Lewis, D., and Reggio, P.H. (2002). N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-p yrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol Pharmacol 62, 1274-1287.
37. Imbernon, M., Whyte, L., Diaz-Arteaga, A., Russell, W.R., Moreno, N.R., Vazquez, M.J., Gonzalez, C.R., Diaz-Ruiz, A., Lopez, M., Malagon, M.M., Ross, R.A., Dieguez, C., and Nogueiras, R. (2014). Regulation of GPR55 in rat white adipose tissue and serum LPI by nutritional status, gestation, gender and pituitary factors. Mol Cell Endocrinol 383, 159-169. doi: 10.1016/j.mce.2013.12.011.
38. Imielinski, M., Baldassano, R.N., Griffiths, A., Russell, R.K., Annese, V., Dubinsky, M., Kugathasan, S., Bradfield, J.P., Walters, T.D., Sleiman, P., Kim, C.E., Muise, A., Wang, K., Glessner, J.T., Saeed, S., Zhang, H., Frackelton, E.C., Hou, C., Flory, J.H., Otieno, G., Chiavacci, R.M., Grundmeier, R., Castro, M., Latiano, A., Dallapiccola, B., Stempak, J., Abrams, D.J., Taylor, K., Mcgovern, D., Western Regional Alliance for Pediatric, I.B.D., Silber, G., Wrobel, I., Quiros, A., International, I.B.D.G.C., Barrett, J.C., Hansoul, S., Nicolae, D.L., Cho, J.H., Duerr, R.H., Rioux, J.D., Brant, S.R., Silverberg, M.S., Taylor, K.D., Barmuda, M.M., Bitton, A., Dassopoulos, T., Datta, L.W., Green, T., Griffiths, A.M., Kistner, E.O., Murtha, M.T., Regueiro, M.D., Rotter, J.I., Schumm, L.P., Steinhart, A.H., Targan, S.R., Xavier, R.J., Consortium, N.I.G., Libioulle, C., Sandor, C., Lathrop, M., Belaiche, J., Dewit, O., Gut, I., Heath, S., Laukens, D., Mni, M., Rutgeerts, P., Van Gossum, A., Zelenika, D., Franchimont, D., Hugot, J.P., De Vos, M., Vermeire, S., Louis, E., Belgian-French, I.B.D.C., Wellcome Trust Case Control, C., Cardon, L.R., Anderson, C.A., Drummond, H., Nimmo, E., Ahmad, T., Prescott, N.J., Onnie, C.M., Fisher, S.A., Marchini, J., Ghori, J., Bumpstead, S., Gwillam, R., Tremelling, M., Delukas, P., Mansfield, J., Jewell, D., Satsangi, J., Mathew, C.G., Parkes, M., Georges, M., Daly, M.J., Heyman, M.B., Ferry, G.D., et al. (2009). Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet 41, 1335-1340. doi: 10.1038/ng.489.
39. Insel, P.A., Tang, C.M., Hahntow, I., and Michel, M.C. (2007). Impact of GPCRs in clinical medicine: monogenic diseases, genetic variants and drug targets. Biochim Biophys Acta 1768, 994-1005. doi: 10.1016/j.bbamem.2006.09.029.
40. Ishiguro, H., Onaivi, E.S., Horiuchi, Y., Imai, K., Komaki, G., Ishikawa, T., Suzuki, M., Watanabe, Y., Ando, T., Higuchi, S., and Arinami, T. (2011). Functional polymorphism in the GPR55 gene is associated with anorexia nervosa. Synapse 65, 103-108. doi: 10.1002/syn.20821.
41. Jenkins, L., Alvarez-Curto, E., Campbell, K., De Munnik, S., Canals, M., Schlyer, S., and Milligan, G. (2011). Agonist activation of the G protein-coupled receptor GPR35 involves transmembrane domain III and is transduced via Galpha(1)(3) and betaarrestin-2. Br J Pharmacol 162, 733-748. doi: 10.1111/j.1476-5381.2010.01082.x.
42. Jenkins, L., Brea, J., Smith, N.J., Hudson, B.D., Reilly, G., Bryant, N.J., Castro, M., Loza, M.I., and Milligan, G. (2010). Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of beta-arrestin-2 and activate Galpha13. Biochem J 432, 451-459. doi: 10.1042/BJ20101287.
43. Johns, D.G., Behm, D.J., Walker, D.J., Ao, Z., Shapland, E.M., Daniels, D.A., Riddick, M., Dowell, S., Staton, P.C., Green, P., Shabon, U., Bao, W., Aiyar, N., Yue, T.L., Brown, A.J., Morrison, A.D., and Douglas, S.A. (2007). The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 152, 825-831.
44. Kapur, A., Zhao, P., Sharir, H., Bai, Y., Caron, M.G., Barak, L.S., and Abood, M.E. (2009). Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem 284, 29817-29827.
45. Kargl, J., Balenga, N.A., Platzer, W., Martini, L., Whistler, J.L., and Waldhoer, M. (2012). The GPCR-associated sorting protein 1 regulates ligand-induced downregulation of GPR55. British journal of pharmacology 165, 2611-2619. doi: 10.1111/j.1476-5381.2011.01562.x.
46. Kargl, J., Brown, A.J., Andersen, L., Dorn, G., Schicho, R., Waldhoer, M., and Heinemann, A. (2013). A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. The Journal of pharmacology and experimental therapeutics. doi: 10.1124/jpet.113.204180.
47. Karlsen, T.H., Schrumpf, E., and Boberg, K.M. (2010). Update on primary sclerosing cholangitis. Dig Liver Dis 42, 390-400. doi: 10.1016/j.dld.2010.01.011.
48. Keelan, P.C., Bielak, L.F., Ashai, K., Jamjoum, L.S., Denktas, A.E., Rumberger, J.A., Sheedy, I.P., Peyser, P.A., and Schwartz, R.S. (2001). Long-term prognostic value of coronary calcification detected by electron-beam computed tomography in patients undergoing coronary angiography. Circulation 104, 412-417.
49. Kenakin, T. (2005). New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 4, 919-927. doi: 10.1038/nrd1875.
50. Kikuchi, T., Ishida, S., Kinoshita, T., Sakuma, S., Sugawara, N., Yamashita, T., and Koike, K. (2002). IL-6 enhances IgE-dependent histamine release from human peripheral blood-derived cultured mast cells. Cytokine 20, 200-209.
51. Kotsikorou, E., Madrigal, K.E., Hurst, D.P., Sharir, H., Lynch, D.L., Heynen-Genel, S., Milan, L.B., Chung, T.D., Seltzman, H.H., Bai, Y., Caron, M.G., Barak, L., Abood, M.E., and Reggio, P.H. (2011a). Identification of the GPR55 Agonist Binding Site Using a Novel Set of High-Potency GPR55 Selective Ligands. Biochemistry 50, 5633-5647.
52. Kotsikorou, E., Madrigal, K.E., Hurst, D.P., Sharir, H., Lynch, D.L., Heynen-Genel, S., Milan, L.B., Chung, T.D., Seltzman, H.H., Bai, Y., Caron, M.G., Barak, L., Abood, M.E., and Reggio, P.H. (2011b). Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry 50, 5633-5647.
53. Kotsikorou, E., Sharir, H., Shore, D.M., Hurst, D.P., Lynch, D.L., Madrigal, K.E., Heynen-Genel, S., Milan, L.B., Chung, T.D., Seltzman, H.H., Bai, Y., Caron, M.G., Barak, L.S., Croatt, M.P., Abood, M.E., and Reggio, P.H. (2013). Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry 52, 9456-9469. doi: 10.1021/bi4008885.
54. Lagerstrom, M.C., and Schioth, H.B. (2008). Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 7, 339-357. doi: 10.1038/nrd2518.
55. Lauckner, J.E., Jensen, J.B., Chen, H.Y., Lu, H.C., Hille, B., and Mackie, K. (2008). GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 105, 2699-2704.
56. Lawson, S.N. (2002). Phenotype and function of somatic primary afferent nociceptive neurones with C-, Adelta- or Aalpha/beta-fibres. Exp Physiol 87, 239-244.
57. Levoye, A., Dam, J., Ayoub, M.A., Guillaume, J.L., and Jockers, R. (2006). Do orphan Gprotein-coupled receptors have ligand-independent functions? New insights from receptor heterodimers. EMBO Rep 7, 1094-1098. doi: 10.1038/sj.embor.7400838.
58. Leyva-Illades, D., and Demorrow, S. (2013). Orphan G protein receptor GPR55 as an emerging target in cancer therapy and management. Cancer Manag Res 5, 147-155. doi: 10.2147/CMAR.S35175.
59. Lin, X.H., Yuece, B., Li, Y.Y., Feng, Y.J., Feng, J.Y., Yu, L.Y., Li, K., Li, Y.N., and Storr, M. (2011). A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents. Neurogastroenterol Motil 23, 862-e342. doi: 10.1111/j.1365-2982.2011.01742.x.
60. Liu, B., Song, S., Jones, P.M., and Persaud, S.J. (2015). GPR55: From orphan to metabolic regulator? Pharmacol Ther 145C, 35-42. doi: 10.1016/j.pharmthera.2014.06.007.
61. Liu, C., Wu, J., Zhu, J., Kuei, C., Yu, J., Shelton, J., Sutton, S.W., Li, X., Yun, S.J., Mirzadegan, T., Mazur, C., Kamme, F., and Lovenberg, T.W. (2009). Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor, GPR81. J Biol Chem 284, 2811-2822. doi: 10.1074/jbc.M806409200.
62. Macglashan, D., Jr. (2008). IgE receptor and signal transduction in mast cells and basophils. Curr Opin Immunol 20, 717-723. doi: 10.1016/j.coi.2008.08.004.
63. Mackenzie, A.E., Caltabiano, G., Kent, T.C., Jenkins, L., Mccallum, J.E., Hudson, B.D., Nicklin, S.A., Fawcett, L., Markwick, R., Charlton, S.J., and Milligan, G. (2014). The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35. Mol Pharmacol 85, 91-104. doi: 10.1124/mol.113.089482.
64. Mackenzie, A.E., Lappin, J.E., Taylor, D.L., Nicklin, S.A., and Milligan, G. (2011). GPR35 as a Novel Therapeutic Target. Front Endocrinol (Lausanne) 2, 68. doi: 10.3389/fendo.2011.00068.
65. Maravillas-Montero, J.L., Burkhardt, A.M., Hevezi, P.A., Carnevale, C.D., Smit, M.J., and Zlotnik, A. (2015). Cutting Edge: GPR35/CXCR8 Is the Receptor of the Mucosal Chemokine CXCL17. J Immunol 194, 29-33. doi: 10.4049/jimmunol.1401704.
66. Mccusker, E.C., Bane, S.E., O'malley, M.A., and Robinson, A.S. (2007). Heterologous GPCR expression: A bottleneck to obtaining crystal structures. Biotechnology Progress 23, 540-547. doi: Doi 10.1021/Bp060349b.
67. Mchugh, D., Hu, S.S., Rimmerman, N., Juknat, A., Vogel, Z., Walker, J.M., and Bradshaw, H.B. (2010a). N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC neuroscience 11, 44. doi: 10.1186/1471-2202-11-44.
68. Mchugh, D., Hu, S.S., Rimmerman, N., Juknat, A., Vogel, Z., Walker, J.M., and Bradshaw, H.B. (2010b). N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci 11, 44.
69. Mckillop, A.M., Moran, B.M., Abdel-Wahab, Y.H., and Flatt, P.R. (2013). Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice. Br J Pharmacol 170, 978-990. doi: 10.1111/bph.12356.
70. Metz, S.A. (1986a). Lysophosphatidylinositol, but not lysophosphatidic acid, stimulates insulin release. A possible role for phospholipase A2 but not de novo synthesis of lysophospholipid in pancreatic islet function. Biochem Biophys Res Commun 138, 720-727.
71. Metz, S.A. (1986b). Putative roles for lysophospholipids as mediators and lipoxygenasemediated metabolites of arachidonic acid as potentiators of stimulus-secretion coupling: dual mechanisms of p-hydroxymercuribenzoic acid-induced insulin release. J Pharmacol Exp Ther 238, 819-832.
72. Milligan, G., Marshall, F., and Rees, S. (1996). G16 as a universal G protein adapter: implications for agonist screening strategies. Trends Pharmacol Sci 17, 235-237.
73. Min, K.D., Asakura, M., Liao, Y., Nakamaru, K., Okazaki, H., Takahashi, T., Fujimoto, K., Ito, S., Takahashi, A., Asanuma, H., Yamazaki, S., Minamino, T., Sanada, S., Seguchi, O., Nakano, A., Ando, Y., Otsuka, T., Furukawa, H., Isomura, T., Takashima, S., Mochizuki, N., and Kitakaze, M. (2010). Identification of genes related to heart failure using global gene expression profiling of human failing myocardium. Biochem Biophys Res Commun 393, 55-60. doi: 10.1016/j.bbrc.2010.01.076.
74. Moreno-Navarrete, J.M., Catalan, V., Whyte, L., Diaz-Arteaga, A., Vazquez-Martinez, R., Rotellar, F., Guzman, R., Gomez-Ambrosi, J., Pulido, M.R., Russell, W.R., Imbernon, M., Ross, R.A., Malagon, M.M., Dieguez, C., Fernandez-Real, J.M., Fruhbeck, G., and Nogueiras, R. (2012). The L-alpha-lysophosphatidylinositol/GPR55 system and its potential role in human obesity. Diabetes 61, 281-291. doi: 10.2337/db11-0649.
75. Noguchi, K., Herr, D., Mutoh, T., and Chun, J. (2009). Lysophosphatidic acid (LPA) and its receptors. Curr Opin Pharmacol 9, 15-23. doi: 10.1016/j.coph.2008.11.010.
76. O'dowd, B.F., Nguyen, T., Marchese, A., Cheng, R., Lynch, K.R., Heng, H.H., Kolakowski, L.F., Jr., and George, S.R. (1998). Discovery of three novel Gprotein-coupled receptor genes. Genomics 47, 310-313.
77. Ohshiro, H., Tonai-Kachi, H., and Ichikawa, K. (2008). GPR35 is a functional receptor in rat dorsal root ganglion neurons. Biochem Biophys Res Commun 365, 344-348. doi: 10.1016/j.bbrc.2007.10.197.
78. Oka, S., Kimura, S., Toshida, T., Ota, R., Yamashita, A., and Sugiura, T. (2010a). Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells. J Biochem 147, 671-678. doi: 10.1093/jb/mvp208.
79. Oka, S., Nakajima, K., Yamashita, A., Kishimoto, S., and Sugiura, T. (2007). Identification of GPR55 as a lysophosphatidylinositol receptor. Biochemical and Biophysical Research Communications 362, 928-934.
80. Oka, S., Ota, R., Shima, M., Yamashita, A., and Sugiura, T. (2010b). GPR35 is a novel lysophosphatidic acid receptor. Biochem Biophys Res Commun 395, 232-237. doi: 10.1016/j.bbrc.2010.03.169.
81. Oka, S., Toshida, T., Maruyama, K., Nakajima, K., Yamashita, A., and Sugiura, T. (2009). 2-Arachidonoyl-sn-glycero-3-phosphoinositol: A Possible Natural Ligand for GPR55. Journal of Biochemistry 145, 13-20.
82. Okada, Y., Tsuzuki, Y., Miyazaki, J., Matsuzaki, K., Hokari, R., Komoto, S., Kato, S., Kawaguchi, A., Nagao, S., Itoh, K., Watanabe, T., and Miura, S. (2006). Propionibacterium freudenreichii component 1.4-dihydroxy-2-naphthoic acid (DHNA) attenuates dextran sodium sulphate induced colitis by modulation of bacterial flora and lymphocyte homing. Gut 55, 681-688. doi: 10.1136/gut.2005.070490.
83. Okumura, S., Baba, H., Kumada, T., Nanmoku, K., Nakajima, H., Nakane, Y., Hioki, K., and Ikenaka, K. (2004). Cloning of a G-protein-coupled receptor that shows an activity to transform NIH3T3 cells and is expressed in gastric cancer cells. Cancer Sci 95, 131-135.
84. Perez-Gomez, E., Andradas, C., Flores, J.M., Quintanilla, M., Paramio, J.M., Guzman, M., and Sanchez, C. (2013). The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. Oncogene 32, 2534-2542. doi: 10.1038/onc.2012.278.
85. Pineiro, R., Maffucci, T., and Falasca, M. (2010). The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 30, 142-152.
86. Pineiro, R., Maffucci, T., and Falasca, M. (2011). The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 30, 142-152. doi: 10.1038/onc.2010.417.
87. Pisabarro, M.T., Leung, B., Kwong, M., Corpuz, R., Frantz, G.D., Chiang, N., Vandlen, R., Diehl, L.J., Skelton, N., Kim, H.S., Eaton, D., and Schmidt, K.N. (2006). Cutting edge: novel human dendritic cell- and monocyte-attracting chemokinelike protein identified by fold recognition methods. J Immunol 176, 2069-2073.
88. Rao, V.V., Schnittger, S., and Hansmann, I. (1991). G protein Gs alpha (GNAS 1), the probable candidate gene for Albright hereditary osteodystrophy, is assigned to human chromosome 20q12-q13.2. Genomics 10, 257-261.
89. Rempel, V., Fuchs, A., Hinz, S., Karcz, T., Lehr, M., Koetter, U., and Muller, C.E. (2012). Magnolia Extract, Magnolol and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55. Med Chem Lett 4, 41-45.
90. Rempel, V., Fuchs, A., Hinz, S., Karcz, T., Lehr, M., Koetter, U., and Muller, C.E. (2013a). Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55. ACS Med Chem Lett 4, 41-45. doi: 10.1021/ml300235q.
91. Rempel, V., Volz, N., Glaser, F., Nieger, M., Brase, S., and Muller, C.E. (2013b). Antagonists for the orphan G protein-coupled receptor GPR55 based on a coumarin scaffold. Journal of Medicinal Chemistry. doi: 10.1021/jm4005175.
92. Romero-Zerbo, S.Y., Rafacho, A., Diaz-Arteaga, A., Suarez, J., Quesada, I., Imbernon, M., Ross, R.A., Dieguez, C., Rodriguez De Fonseca, F., Nogueiras, R., Nadal, A., and Bermudez-Silva, F.J. (2011). A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans. J Endocrinol 211, 177-185. doi: 10.1530/JOE-11-0166.
93. Ronkainen, V.P., Tuomainen, T., Huusko, J., Laidinen, S., Malinen, M., Palvimo, J.J., Yla-Herttuala, S., Vuolteenaho, O., and Tavi, P. (2014). Hypoxia-inducible factor 1-induced G protein-coupled receptor 35 expression is an early marker of progressive cardiac remodelling. Cardiovasc Res 101, 69-77. doi: 10.1093/cvr/cvt226.
94. Rossi, F., Siniscalco, D., Luongo, L., De Petrocellis, L., Bellini, G., Petrosino, S., Torella, M., Santoro, C., Nobili, B., Perrotta, S., Di Marzo, V., and Maione, S. (2009). The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone 44, 476-484. doi: 10.1016/j.bone.2008.10.056.
95. Ruban, E.L., Ferro, R., Arifin, S.A., and Falasca, M. (2014). Lysophosphatidylinositol: a novel link between ABC transporters and G-protein-coupled receptors. Biochem Soc Trans 42, 1372-1377. doi: 10.1042/BST20140151.
96. Ryberg, E., Larsson, N., Sjogren, S., Hjorth, S., Hermansson, N.O., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., and Greasley, P.J. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152, 1092-1101.
97. Sawzdargo, M., Nguyen, T., Lee, D.K., Lynch, K.R., Cheng, R., Heng, H.H., George, S.R., and O'dowd, B.F. (1999). Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res 64, 193-198.
98. Schicho, R., Bashashati, M., Bawa, M., Mchugh, D., Saur, D., Hu, H.M., Zimmer, A., Lutz, B., Mackie, K., Bradshaw, H.B., Mccafferty, D.M., Sharkey, K.A., and Storr, M. (2011). The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm Bowel Dis 17, 1651-1664.
99. Schmuhl, E., Ramer, R., Salamon, A., Peters, K., and Hinz, B. (2014). Increase of mesenchymal stem cell migration by cannabidiol via activation of p42/44 MAPK. Biochem Pharmacol 87, 489-501. doi: 10.1016/j.bcp.2013.11.016.
100. Shrimpton, A.E., Braddock, B.R., Thomson, L.L., Stein, C.K., and Hoo, J.J. (2004). Molecular delineation of deletions on 2q37.3 in three cases with an Albright hereditary osteodystrophy-like phenotype. Clin Genet 66, 537-544. doi: 10.1111/j.1399-0004.2004.00363.x.
101. Simcocks, A.C., O'keefe, L., Jenkin, K.A., Mathai, M.L., Hryciw, D.H., and Mcainch, A.J. (2014). A potential role for GPR55 in the regulation of energy homeostasis. Drug Discov Today 19, 1145-1151. doi: 10.1016/j.drudis.2013.12.005.
102. Song, Z.H., and Bonner, T.I. (1996). A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol Pharmacol 49, 891-896.
103. Southern, C., Cook, J.M., Neetoo-Isseljee, Z., Taylor, D.L., Kettleborough, C.A., Merritt, A., Bassoni, D.L., Raab, W.J., Quinn, E., Wehrman, T.S., Davenport, A.P., Brown, A.J., Green, A., Wigglesworth, M.J., and Rees, S. (2013). Screening beta-arrestin recruitment for the identification of natural ligands for orphan Gprotein-coupled receptors. J Biomol Screen 18, 599-609. doi: 10.1177/1087057113475480.
104. Sparfel, L., Pinel-Marie, M.L., Boize, M., Koscielny, S., Desmots, S., Pery, A., and Fardel, O. (2010). Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci 114, 247-259. doi: 10.1093/toxsci/kfq007.
105. Sugiura, T., Nakane, S., Kishimoto, S., Waku, K., Yoshioka, Y., Tokumura, A., and Hanahan, D.J. (1999). Occurrence of lysophosphatidic acid and its alkyl etherlinked analog in rat brain and comparison of their biological activities toward cultured neural cells. Biochim Biophys Acta 1440, 194-204.
106. Sun, Y.V., Bielak, L.F., Peyser, P.A., Turner, S.T., Sheedy, P.F., 2nd, Boerwinkle, E., and Kardia, S.L. (2008). Application of machine learning algorithms to predict coronary artery calcification with a sibship-based design. Genet Epidemiol 32, 350-360. doi: 10.1002/gepi.20309.
107. Taniguchi, Y., Tonai-Kachi, H., and Shinjo, K. (2006). Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35. FEBS Lett 580, 5003-5008.
108. Unal, H., Jagannathan, R., Bhat, M.B., and Karnik, S.S. (2010). Ligand-specific conformation of extracellular loop-2 in the angiotensin II type 1 receptor. J Biol Chem 285, 16341-16350. doi: 10.1074/jbc.M109.094870.
109. Vander Molen, J., Frisse, L.M., Fullerton, S.M., Qian, Y., Del Bosque-Plata, L., Hudson, R.R., and Di Rienzo, A. (2005). Population genetics of CAPN10 and GPR35: implications for the evolution of type 2 diabetes variants. Am J Hum Genet 76, 548-560. doi: 10.1086/428784.
110. Wang, C.I., and Lewis, R.J. (2013). Emerging opportunities for allosteric modulation of G-protein coupled receptors. Biochem Pharmacol 85, 153-162. doi: 10.1016/j.bcp.2012.09.001.
111. Wang, J., Simonavicius, N., Wu, X., Swaminath, G., Reagan, J., Tian, H., and Ling, L. (2006). Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 281, 22021-22028.
112. Whyte, L.S., Ryberg, E., Sims, N.A., Ridge, S.A., Mackie, K., Greasley, P.J., Ross, R.A., and Rogers, M.J. (2009). The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A 106, 16511-16516.
113. Wu, B., Chien, E.Y., Mol, C.D., Fenalti, G., Liu, W., Katritch, V., Abagyan, R., Brooun, A., Wells, P., Bi, F.C., Hamel, D.J., Kuhn, P., Handel, T.M., Cherezov, V., and Stevens, R.C. (2010). Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists. Science 330, 1066-1071.
114. Xiao, Y., Chen, Y., Kennedy, A.W., Belinson, J., and Xu, Y. (2000). Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. Ann N Y Acad Sci 905, 242-259.
115. Yang, S.K., Hong, M., Choi, H., Zhao, W., Jung, Y., Haritunians, T., Ye, B.D., Kim, K.J., Park, S.H., Lee, I., Kim, W.H., Cheon, J.H., Kim, Y.H., Jang, B.I., Kim, H.S., Choi, J.H., Koo, J.S., Lee, J.H., Jung, S.A., Shin, H.D., Kang, D., Youn, H.S., Taylor, K.D., Rotter, J.I., Liu, J., Mcgovern, D.P., and Song, K. (2015). Immunochip analysis identification of 6 additional susceptibility Loci for Crohn's disease in koreans. Inflamm Bowel Dis 21, 1-7. doi: 10.1097/MIB.0000000000000268.
116. Yang, Y., Fu, A., Wu, X., and Reagan, J.D. (2012). GPR35 is a target of the loop diuretic drugs bumetanide and furosemide. Pharmacology 89, 13-17. doi: 10.1159/000335127.
117. Yang, Y., Lu, J.Y., Wu, X., Summer, S., Whoriskey, J., Saris, C., and Reagan, J.D. (2010). G-protein-coupled receptor 35 is a target of the asthma drugs cromolyn disodium and nedocromil sodium. Pharmacology 86, 1-5. doi: 10.1159/000314164.
118. Yin, H., Chu, A., Li, W., Wang, B., Shelton, F., Otero, F., Nguyen, D.G., Caldwell, J.S., and Chen, Y.A. (2009). Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem 284, 12328-12338.
119. Zhao, P., and Abood, M.E. (2013). GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors. Life Sci 92, 453-457. doi: 10.1016/j.lfs.2012.06.039.
120. Zhao, P., Lane, T.R., Gao, H.G., Hurst, D.P., Kotsikorou, E., Le, L., Brailoiu, E., Reggio, P.H., and Abood, M.E. (2014). Crucial positively charged residues for ligand activation of the GPR35 receptor. J Biol Chem 289, 3625-3638. doi: 10.1074/jbc.M113.508382.
121. Zhao, P., Sharir, H., Kapur, A., Cowan, A., Geller, E.B., Adler, M.W., Seltzman, H.H., Reggio, P.H., Heynen-Genel, S., Sauer, M., Chung, T.D., Bai, Y., Chen, W., Caron, M.G., Barak, L.S., and Abood, M.E. (2010). Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signalregulated kinase and beta-arrestin2 with antinociceptive activity. Mol Pharmacol 78, 560-568.